Physician profile
Bridget Beck
NPI 1922281534
$3,796.37
in general payments reported to CMS, 2019-2025
32 companies · $34.62 in 2025
The $34.62 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $144 · 2021: $364 · 2022: $439 · 2023: $458 · 2024: $488 · 2025: $34.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,616.25 | 2019-2025 | Mitraclip, Jot Dx |
| Pfizer INC. | $242.13 | 2019-2024 | |
| Amgen INC. | $227.84 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $206.06 | 2019-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $174.70 | 2021-2024 | Verquvo |
| Medtronic, INC. | $140.91 | 2021 | |
| Philips North America LLC | $138.28 | 2022-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.15 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $89.41 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $87.88 | 2024 | Uptravi, Opsumit |
| Veryan Medical Incorporated | $86.53 | 2023-2024 | Biomimics 3d Vascular Stent System |
| Boston Scientific Corporation | $68.20 | 2022-2023 | Watchman Access System |
| Medtronic Vascular, INC. | $64.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.12 | 2019-2022 | |
| Inspire Medical Systems, INC. | $55.43 | 2023 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $46.89 | 2021-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.53 | 2019-2022 | |
| Lundbeck LLC | $40.07 | 2019-2021 | |
| Biotronik INC. | $29.54 | 2022 | |
| Cvrx, INC. | $26.92 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $24.97 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.86 | 2022 | |
| Astellas Pharma US INC | $23.38 | 2019 | |
| Esperion Therapeutics, INC. | $22.33 | 2021 | |
| Novo Nordisk INC | $19.82 | 2023 | |
| Itamar Medical INC | $19.74 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.33 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $16.65 | 2021 | |
| Gilead Sciences, INC. | $14.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.84 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.